Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections

American Journal of Health-System Pharmacy

Volumn 68, Issue 13, 2011, Pages 1207-1220

  Holt, Shannon L ^a   Drew, Richard H ^b,c  

^a WAKEMED HEALTH AND HOSPITALS   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CAMPBELL UNIVERSITY   (United States)

Author keywords

Anidulafungin; Antifungals; Aspergillosis; Candidiasis; Caspofungin; Costs; Dosage; Drugs; Echinocandins; Mycofungin; Mycoses; Pediatrics; Pharmacoeconomics; Resistance; Toxicity

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ASPERGILLOSIS; ASPERGILLUS; BIOFILM; CANDIDA; CANDIDA PARAPSILOSIS; CANDIDIASIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC MYCOSIS; TREATMENT INDICATION; YEAST;

EID: 79960170049     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100456     Document Type: Review

References (114)

1. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008; 32(suppl 2):S87-91.
2. Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003; 37:634-43. (Pubitemid 37100802)
3. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20:133-63. (Pubitemid 46167771)
4. Segal BH. Aspergillosis. N Engl J Med. 2009; 360:1870-84.
5. Singh N. Evidence-based approach to challenging issues in the management of invasive aspergillosis. Med Mycol. 2009; 47(suppl 1):S338-42.
6. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:327-60. (Pubitemid 351265310)
7. Cancidas (caspofungin) package insert. Whitehouse Station, NJ: Merck & Co. Inc.; 2009.
8. Eraxis (anidulafungin) package insert. New York: Pfizer, Inc.; 2010.
9. Mycamine (micafungin) package insert. Deerfield, IL: Astellas Pharma US, Inc.; 2008.
10. Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007; 7:369-88. (Pubitemid 46327905)
11. Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007; 3:71-97.
12. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35.
13. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health-Syst Pharm. 2006; 63:1693-703. (Pubitemid 44413505)
14. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health-Syst Pharm. 2006; 63:1813-20. (Pubitemid 44477452)
15. CLSI M27-A3(28). In: Rex JH, ed. Reference methods for broth dilution antifungal susceptibility testing of yeasts: approved standard. 3rd ed. Wayne, NJ: Clinical and Laboratory Standards Institute; 2008.
16. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008; 46:2620-9.
17. Pfaller MA, Boyken L, Hollis RJ et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010; 48:52-6.
18. Diekema DJ, Messer SA, Boyken LB et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009; 47:3170-7.
19. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008; 46:150-6.
20. Ghannoum MA, Chen A, Buhari M et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin Microbiol Infect. 2009; 15:274-9.
21. Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother. 2010; 65:293-5.
22. Lyon GM, Karatela S, Sunay S et al. Antifungal susceptibility testing of Candida isolates from the Candida surveillance study. J Clin Microbiol. 2010; 48:1270-5.
23. Pfaller MA, Diekema DJ, Gibbs DL et al. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol. 2008; 46:842-9.
24. Lass-Florl C, Alastruey-Izquierdo A, Cuenca-Estrella M et al. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2009; 53:794-5.
25. Lass-Florl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses. 2010; 53:1-11.
26. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head to head comparison using the CLSI M38-A2 broth microdilution method. J Clin Microbiol. 2009; 47:3323-5.
27. Arendrup MC, Garcia-Effron G, Lass-Florl C et al. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob Agents Chemother. 2010; 54:426-39.
28. Garcia-Effron G, Lee S, Park S et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009; 53:3690-9.
29. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of FKS1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009; 53:112-22.
30. Bachmann SP, Ramage G, VandeWalle K et al. Antifungal combinations against Candida albicans biofilms in vitro. Antimicrob Agents Chemother. 2003; 47:3657-9. (Pubitemid 37345743)
31. Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002; 46:1773-80. (Pubitemid 34535196)
32. Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother. 2007; 51:1520-3. (Pubitemid 46586842)
33. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother. 2008; 52:357-60.
34. Jacobson MJ, Piper KE, Nguyen G et al. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2008; 52:2242-3. (Pubitemid 351758568)
35. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004; 48:3407-11. (Pubitemid 39129338)
36. Stevens DA, White TC, Perlin DS et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis. 2005; 51:173-8. (Pubitemid 40568760)
37. Chamilos G, Lewis RE, Albert N et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother. 2007; 51:2257-9. (Pubitemid 46903132)
38. Marine M, Pastor FJ, Sahand IH et al. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. Antimicrob Agents Chemother. 2009; 53:5297-9.
39. Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J Antimicrob Chemother. 2008; 61:1140-4. (Pubitemid 351524462)
40. Kang CI, Rouse MS, Mandrekar JN et al. Anidulafungin treatment of candidal central nervous system infection in a murine model. Antimicrob Agents Chemother. 2009; 53:3576-8.
41. Lat A, Thompson GR III, Rinaldi MG et al. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob Agents Chemother. 2010; 54:943-4.
42. Crandon JL, Banevicius MA, Fang AF et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009; 53:5102-7.
43. Nicasio AM, Tessier PR, Nicolau DP et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother. 2009; 53:1218-20.
44. Walsh TJ, Goutelle S, Jelliffe RW et al. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob Agents Chemother. 2010; 54:3451-9.
45. Carter NJ, Keating GM. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs. 2009; 11:271-91.
46. Garnock-Jones KP, Keam SJ. Caspofungin: in pediatric patients with fungal infections. Paediatr Drugs. 2009; 11:259-69.
47. VandenBussche HL, Van Loo DA. A clinical review of echinocandins in pediatric patients. Ann Pharmacother. 2010; 44:166-77.
48. Kawada M, Fukuoka N, Kondo M et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J. 2009; 28:840-2.
49. Benjamin DK Jr, Smith PB, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010; 87:93-9.
50. Neely M, Jafri HS, Seibel N et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009; 53:1450-6.
51. Saez-Llorens X, Macias M, Maiya P et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009; 53:869-75.
52. Spriet I, Annaert P, Meersseman P et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2009; 63:767-70.
53. Dowell JA, Stogniew M, Krause D et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007; 47:461-70. (Pubitemid 46465954)
54. Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother. 2010; 65:1108-18.
55. Andes DR, Diekema DJ, Pfaller MA et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008; 52:3497-503.
56. Andes D, Diekema DJ, Pfaller MA et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010; 54:2497-506.
57. Ikawa K, Nomura K, Morikawa N et al. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergil lus infections. J Antimicrob Chemother. 2009; 64:840-4.
58. Nguyen KT, Ta P, Hoang BT et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother. 2009; 53:3347-52.
59. Castagnola E, Machetti M, Cappelli B et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin Microbiol Infect. 2004; 10:255-7. (Pubitemid 38379966)
60. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J. 2003; 22:747-9. (Pubitemid 36999657)
61. Hesseling M, Weindling M, Neal T. First reported use of caspofungin in an extremely low-birth-weight neonate. J Matern Fetal Neonatal Med. 2003; 14:212. (Pubitemid 37186644)
62. Krause DS, Reinhardt J, Vazquez JA et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004; 48:2021-4. (Pubitemid 38691592)
63. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002; 347:2020-9. (Pubitemid 35461658)
64. Mrowczynski W, Wojtalik M. Caspofungin for Candida endocarditis. Pediatr Infect Dis J. 2004; 23:376.
65. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005; 24:654-61. (Pubitemid 41667052)
66. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356:2472-82. (Pubitemid 46919773)
67. Wertz KK, Pretzlaff RK. Caspofungin in a pediatric patient with persistent candidemia. Pediatr Crit Care Med. 2004; 5:181-3.
68. Betts RF, Nucci M, Talwar D et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis. 2009; 48:1676-84.
69. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007; 45:883-93. (Pubitemid 47580382)
70. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007; 369:1519-27. (Pubitemid 46670281)
71. Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008; 27:820-6.
72. Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009; 123:877-84.
73. Garcia-Effron G, Kontoyiannis DP, Lewis RE et al. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008; 52:4181-3.
74. Arendrup MC, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother. 2009; 53:1185-93.
75. Pasquale T, Tomada JR, Ghannoun M et al. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother. 2008; 61:219.
76. Pfeiffer CD, Garcia-Effron G, Zaas AK et al. Breakthrough invasive candidiasis on micafungin. J Clin Microbiol. 2010; 48:2373-80.
77. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004; 39:1563-71. (Pubitemid 39578526)
78. Kartsonis NA, Saah A, Lipka CJ et al. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionateuse study. J Antimicrob Chemother. 2004; 53:878-81. (Pubitemid 38660297)
79. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006; 53:337-49. (Pubitemid 44524711)
80. Flynn PM, Seibel N, Arrieta A. Treatment of invasive aspergillosis (ia) in pediatric patients (pts) with micafungin (mica) alone or in combination with other systemic antifungal agents. Presented at 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology Annual Meeting. San Francisco, CA; 2006 Sep.
81. Kontoyiannis DP, Ratanatharathorn V, Young JA et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infect Dis. 2009; 11:89-93.
82. Caillot D, Thiebaut A, Herbrecht R et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007; 110:2740-6. (Pubitemid 350250344)
83. Herbrecht R, Maertens J, Baila L et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer Study. Bone Marrow Transplant. 2010; 45:1227-33.
84. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009; 64:1274-81.
85. Groetzner J, Kaczmarek I, Wittwer T et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008; 27:1-6.
86. Mattiuzzi GN, Alvarado G, Giles FJ et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006; 50:143-7. (Pubitemid 43042914)
87. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004; 39:1407-16. (Pubitemid 39518200)
88. Fortun J, Martin-Davila P, Montejo M et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009; 87:424-35.
89. Kriengkauykiat J, Tegtmeier B, Dadwal S et al. Amphotericin B lipid complex versus micafungin as antifungal prophylaxis in allogeneic hematopoietic cell transplantation. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology Annual Meeting. San Francisco, CA; 2009 Sep.
90. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. www.nccn.org/professionals/physician-gls/PDF/ infections.pdf (accessed 2009 Jul 8).
91. Pappas PG, Silveira FP, AST Infectious Diseases Community of Practice. Candida in solid organ transplant recipients. Am J Transplant. 2009; 9(suppl 4):S173-9.
92. Lafaurie M, Lapalu J, Raffoux E et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect. 2010; 16:1191-6.
93. Koo A, Sung L, Allen U et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J. 2007; 26:854-6. (Pubitemid 47329864)
94. Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother. 2008; 62:153-5. (Pubitemid 351865889)
95. Spellberg B, Walsh TJ, Kontoyiannis D et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48:1743-51.
96. Alastruey-Izquierdo A, Castelli MV, Cuesta I et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect. 2009; 15(suppl 5):71-6.
97. Spellberg B, Fu Y, Edwards JE et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005; 49:830-2. (Pubitemid 40175710)
98. Ibrahim AS, Gebremariam T, Fu Y et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008; 52:1556-8. (Pubitemid 351522035)
99. Reed C, Bryant R, Ibrahim AS. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008; 47:364-71. (Pubitemid 352009357)
100. DiNubile MJ, Strohmaier KM, Lupinacci RJ et al. Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections. Eur J Clin Microbiol Infect Dis. 2008; 27:663-70.
101. Zaoutis T, Lehrnbecher T, Groll AH et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009; 28:1132-5.
102. Selleslag D, Vogelaers D, Marbaix S. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium. Acta Clinica Belgica. 2009; 64:393-8.
103. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care. 2009; 13:R94.
104. Sidhu MK, van Engen AK, Kleintjens J et al. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Curr Med Res Opin. 2009; 25:2049-59.
105. Cornely OA, Sidhu M, Odeyemi I et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008; 24:1743-53. (Pubitemid 351929071)
106. Sohn HS, Lee TJ, Kim J et al. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009; 31:1105-15.
107. Schonfeld W, Wang CJ, Tong KB et al. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation. Clin Ther. 2008; 30:964-73. (Pubitemid 351799867)
108. Al Badriyeh D, Liew D, Stewart K et al. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J Antimicrob Chemother. 2009; 63:1276-85.
109. Bruynesteyn K, Gant V, McKenzie C et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007; 78:532-9. (Pubitemid 46753596)
110. Stam WB, Aversa F, Kumar RN et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health. 2008; 11:830-41.
111. Wingard JR, Leather HL, Wood CA et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health-Syst Pharm. 2007; 64:637-43. (Pubitemid 46481865)
112. Barchiesi F, Spreghini E, Tomassetti S et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006; 50:2719-27. (Pubitemid 44198693)
113. Kartsonis N, Killar J, Mixson L et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005; 49:3616-23. (Pubitemid 41233008)
114. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect. 2008; 56:126-9.